SCHEMBL353201

SCHEMBL353201

Cc1nc2ccccc2c(C(=O)O)c1C(=O)O

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 3/20 0.77
KMT2A Q03164 3/20 0.76
MEN1 O00255 2/20 0.76
HSD17B10 Q99714 2/20 0.62
TP53 P04637 1/20 0.62
HTT P42858 3/20 0.60
TSHR P16473 1/20 0.60
DHODH Q02127 2/20 0.57
GAA P10253 1/20 0.57
MAPT P10636 1/20 0.57
NPSR1 Q6W5P4 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.54
GPR3 P46089 1/20 0.53
ALDH1A1 P00352 2/20 0.53
CYP1A2 P05177 1/20 0.53
HPGD P15428 1/20 0.53
NUDT1 P36639 1/20 0.53
LMNA P02545 1/20 0.53
KDM4E B2RXH2 1/20 0.53
CYP2D6 P10635 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29415444 1.00 PDE10A (0.77) PDE10AKMT2AMEN1HSD17B10TP53
SCHEMBL29952587 0.91 HSD17B10 (0.71) PDE10AKMT2AMEN1HSD17B10TP53
SCHEMBL13957825 0.87 PDE10A (1.00) PDE10AKMT2AMEN1HSD17B10TP53
SCHEMBL10265349 0.87 PDE10A (0.74) PDE10AKMT2AMEN1HSD17B10TP53
SCHEMBL1527122 0.85 PDE10A (0.72) PDE10AKMT2AMEN1HSD17B10TP53
SCHEMBL11056730 0.85 PDE10A (0.67) PDE10AKMT2AMEN1HSD17B10TP53
SCHEMBL620119 0.84 HSD17B10 (0.81) PDE10AKMT2AMEN1HSD17B10TP53
SCHEMBL28083850 0.84 PDE10A (0.70) PDE10AKMT2AMEN1HSD17B10TP53
SCHEMBL4230349 0.84 PDE10A (0.70) PDE10AKMT2AMEN1HSD17B10TP53
SCHEMBL27837402 0.83 KMT2A (0.56) PDE10AKMT2AMEN1HSD17B10TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 391 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260042084-A1 SORBENTS FUNCTIONALIZED WITH LIGANDS HAVING AN AMINOSILICONE FUNCTIONAL GROUP GENERAL ELECTRIC TECHNOLOGY GMBH (CH) 2026-02-12 US claimed
WO-2025238576-A1 SYSTEM AND METHOD FOR STORING LIQUIDS HAVING LOW LATENT HEAT OF VAPORIZATION Nuovo Pignone Tecnologie – S.r.l. (IT) 2025-11-20 WO claimed
US-20250354659-A1 SYSTEM AND METHOD FOR STORING LIQUIDS HAVING LOW LATENT HEAT OF VAPORIZATION NUOVO PIGNONE TECNOLOGIE – S R L (IT) 2025-11-20 US claimed
EP-4556112-A2 SORBENT COMPOSITIONS, SYSTEMS, AND METHODS General Electric Technology GmbH (CH) 2025-05-21 EP claimed
US-12263464-B2 Method for in-situ synthesis of metal organic frameworks (MOFs), covalent organic frameworks (COFs) and zeolite imidazolate frameworks (ZIFs), and applications thereof DESICCANT ROTORS INTERNATIONAL PRIVATE LIMITED (IN) 2025-04-01 US claimed
US-20240199653-A1 METHOD FOR FORMING AN ELECTRICALLY CONDUCTIVE METAL ORGANIC FRAMEWORK COMPOSITE KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2024-06-20 US claimed
WO-2024123903-A1 SORBENT COMPOSITIONS, SYSTEMS, AND METHODS GE INFRASTRUCTURE TECHNOLOGY LLC (US) 2024-06-13 WO claimed
WO-2024039914-A1 SORBENTS FUNCTIONALIZED WITH LIGANDS HAVING AN AMINOSILICONE FUNCTIONAL GROUP GENERAL ELECTRIC TECHNOLOGY GMBH (CH) 2024-02-22 WO claimed
EP-3801880-A1 METHOD FOR IN-SITU SYNTHESIS OF METAL ORGANIC FRAMEWORKS (MOFS), COVALENT ORGANIC FRAMEWORKS (COFS) AND ZEOLITE IMIDAZOLATE FRAMEWORKS (ZIFS), AND APPLICATIONS THEREOF Desiccant Rotors International Private Ltd. (IN) 2021-04-14 EP claimed
US-20210016245-A1 METHOD FOR IN-SITU SYNTHESIS OF METAL ORGANIC FRAMEWORKS (MOFs), COVALENT ORGANIC FRAMEWORKS (COFs) AND ZEOLITE IMIDAZOLATE FRAMEWORKS (ZIFs), AND APPLICATIONS THEREOF DESICCANT ROTORS INTERNATIONAL PRIVATE LIMITED (IN) 2021-01-21 US claimed
WO-2013019865-A2 POROUS CATALYTIC MATRICES FOR ELIMINATION OF TOXICANTS FOUND IN TOBACCO COMBUSTION PRODUCTS MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2013-02-07 WO claimed
US-8048896-B2 Inhibit nonenzymatic formation of advanced glycation end-products (AGE) using e.g. aminoguanidine, OPB-9195 [(+/-)-2-isopropylidenehydrazono-4-oxo-thiazolidin-5-yla cetanilide], pyridoxamine, antioxidants, alagebrium, antihypertensives, angiotensin-converting enzyme inhibitors Cell Viable Corporation (US) 2011-11-01 US claimed
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT L'OREAL (FR) 2010-10-28 US claimed
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS L'OREAL (FR) 2010-09-23 US claimed
US-20090130384-A1 Chip Provided with film Having Hole Pattern with the Use of Thermoresponsive Polymer and Method of Producing the Same TOYAMA PREFECTURE (JP) 2009-05-21 US claimed
EP-1942179-A1 CHIP PROVIDED WITH FILM HAVING HOLE PATTERN WITH THE USE OF THERMORESPONSIVE POLYMER AND METHOD OF PRODUCING THE SAME Toyama Prefecture (JP) 2008-07-09 EP claimed
EP-1165064-B1 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) HOPE CITY (US) 2004-02-25 EP claimed
US-6337350-B1 CROSSLINKING INHIBITION OF PROTEINS CITY OF HOPE 2002-01-08 US claimed
EP-1165064-A2 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) City of Hope (US) 2002-01-02 EP claimed
WO-2000059875-A2 NOVEL INHIBITORS OF FORMATION OF ADVANCED GLYCATION ENDPRODUCTS (AGE'S) CITY OF HOPE (US) 2000-10-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042084-A1 SORBENTS FUNCTIONALIZED WITH LIGANDS HAVING AN AMINOSILICONE FUNCTIONAL GROUP SRMS, TYRO3, SELE PDE10A 3863/4885KMT2A 2367/4885MEN1 4244/4885
US-20100239509-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A POLYMER BEARING JUNCTION GROUPS, AND COSMETIC TREATMENT PROCESS CUTA, SUCLG1, KRT18 PDE10A 2442/4885KMT2A 2242/4885MEN1 2029/4885
US-20100272660-A1 COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT ACMSD, CUTA, PCCA PDE10A 1815/4885KMT2A 1122/4885MEN1 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.